Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes
Eligible age
30–80 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.
Sponsor: Hospital de Clinicas de Porto Alegre
You may qualify if…
- ✓ Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;
- ✓ Age over 30 years;
- ✓ BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;
- ✓ HbA1c between 7.5% and 10.5%.
You may not qualify if…
- ✕ Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;
- ✕ Pregnancy or lactation;
- ✕ Chronic renal failure with glomerular filtration rate calculated by MDRD \< 30 mL/h;
- ✕ Myocardial infarction in the last than 6 months
- ✕ Current neoplasia;
- ✕ Chronic use of glucocorticoids;
- ✕ Bariatric surgery.
Source: ClinicalTrials.gov · NCT04874012 · last updated 2026-09-24